Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 1040 Download: 113 Crossref: 2

Original Article

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2024;30(3):487-499. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0145

View: 870 Download: 108

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 1365 Download: 164 Crossref: 1

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 1733 Download: 42 Crossref: 1

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2092 Download: 122 Web of Science: 3 Crossref: 5

Editorial

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 1889 Download: 70 Web of Science: 1 Crossref: 1

Snapshot

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Young Chang, Soung Won Jeong, Jae Young Jang

Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0356

View: 2267 Download: 127 Crossref: 2

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 1389 Download: 38

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 1377 Download: 40 Crossref: 1

Letter to the Editor

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 1922 Download: 49 Web of Science: 2 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 1693 Download: 67 Web of Science: 1 Crossref: 1

Original Article

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0366

View: 3452 Download: 103 Web of Science: 3 Crossref: 4

Review

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 5404 Download: 278 Web of Science: 9 Crossref: 8

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3402 Download: 200 Web of Science: 8 Crossref: 11

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 3347 Download: 115 Web of Science: 5 Crossref: 5

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 3666 Download: 134 Web of Science: 3 Crossref: 4

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 7524 Download: 165 Web of Science: 6 Crossref: 11

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 5772 Download: 279 Web of Science: 8 Crossref: 9

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0426

View: 4763 Download: 269 Web of Science: 7 Crossref: 7

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 3898 Download: 227 Web of Science: 7 Crossref: 8

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4170 Download: 221 Web of Science: 17 Crossref: 16

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4082 Download: 197 Web of Science: 11 Crossref: 12

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 4981 Download: 231 Web of Science: 13 Crossref: 14

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 5136 Download: 207 Web of Science: 8 Crossref: 9

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 4545 Download: 229 Web of Science: 21 Crossref: 22

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 5451 Download: 269 Web of Science: 15 Crossref: 18

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 4159 Download: 166 Web of Science: 20 Crossref: 20

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 10554 Download: 444 Web of Science: 88 Crossref: 108

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 6965 Download: 497 Web of Science: 34 Crossref: 36

Correspondence

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):1050-1051. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0310

View: 1642 Download: 38

1 | 2 | 3 | 4 | 5 | 6 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5409	MAFLD: How is it different from NAFLD?
Viewed By 5220	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5098	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search